These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. FDA notifications. Tentative approval to Aptivus for combination ART. AIDS Alert; 2007 Dec; 22(12):144. PubMed ID: 18411486 [No Abstract] [Full Text] [Related]
6. Aptivus in the hotseat. Excerpts from the FDA hearings. Huff B GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577 [No Abstract] [Full Text] [Related]
7. FDA notifications. New tipranavir solution approved. AIDS Alert; 2008 Aug; 23(8):92. PubMed ID: 18724491 [No Abstract] [Full Text] [Related]
8. Aptivus capsules granted full FDA approval. AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430 [No Abstract] [Full Text] [Related]
9. Anti-HIV agents. Unexpected results from a tipranavir study. TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836 [No Abstract] [Full Text] [Related]
10. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling. AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242 [No Abstract] [Full Text] [Related]
11. Tipranavir: new drug. HIV protease inhibitor. A last resort. Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925 [TBL] [Abstract][Full Text] [Related]
13. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H; Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833 [TBL] [Abstract][Full Text] [Related]